

Anti-D immunoglobulin

Section	Indications
Human immunoglobulins Parenteral > General injections > IV: 250 µg in single-dose vial Parenteral > General injections > IM: 250 µg in single-dose vial	Rh incompatibility reaction Maternal care for red cell antibodies

Anti-rabies immunoglobulin

Section	Indications
Human immunoglobulins Parenteral > General injections > IM: 150 IU per mL in vial Parenteral > Locoregional injections > Other: 150 IU per mL in vial	Rabies

Anti-tetanus immunoglobulin

Section	Indications
Human immunoglobulins Parenteral > General injections > IM: 500 IU in vial	Tetanus

C1 esterase inhibitor

Section	Indications
Plasma-derived medicines Parenteral > General injections > IV: 500 IU in vial powder for injection	Hereditary angioedema

Coagulation factor IX complex

Section	Indications
Coagulation factors	Therapeutic equivalent to coagulation factor IX, plasma-derived pour Coagulation defects, purpura or other haemorrhagic or related conditions Therapeutic equivalent to coagulation factor IX, plasma-derived pour Haemophilia B

Coagulation factor IX, plasma-derived

Section	Indications
Coagulation factors Parenteral > General injections > IV: 500 IU in vial powder for injection; 1000 IU in vial powder for injection	Coagulation defects, purpura or other haemorrhagic or related conditions Haemophilia B

Coagulation factor IX, recombinant

Section

Coagulation factors

Parenteral > General injections > IV: 250 IU per mL in vial lyophilized powder for solution for injection; 500 IU in vial lyophilized powder for solution for injection; 1000 IU in vial lyophilized powder for solution for injection; 1500 IU in vial lyophilized powder for solution for injection; 2000 IU in vial lyophilized powder for solution for injection; 3000 IU in vial lyophilized powder for solution for injection; 4000 IU in vial lyophilized powder for solution for injection

Indications

Haemophilia B

Coagulation factor VIII, plasma-derived

Section

Coagulation factors

Parenteral > General injections > IV: 250 IU in vial powder for injection; 500 IU in vial powder for injection; 1000 IU in vial powder for injection

Indications

Haemophilia A

Coagulation factor VIII, recombinant

Section

Coagulation factors

Parenteral > General injections > IV: 250 IU in vial lyophilized powder for solution for injection; 500 IU in vial lyophilized powder for solution for injection; 1000 IU in vial lyophilized powder for solution for injection; 1500 IU in vial lyophilized powder for solution for injection; 2000 IU in vial lyophilized powder for solution for injection; 3000 IU in vial lyophilized powder for solution for injection; 4000 IU in vial lyophilized powder for solution for injection

Indications

Haemophilia A

Cryoprecipitate (not pathogen-reduced)

Section	Indications
Blood and blood components	<p>Therapeutic equivalent to cryoprecipitate (pathogen-reduced) pour</p> <p>Coagulation defects, purpura or other haemorrhagic or related conditions</p> <p>Therapeutic equivalent to cryoprecipitate (pathogen-reduced) pour</p> <p>Obstetric haemorrhage</p> <p>Therapeutic equivalent to cryoprecipitate (pathogen-reduced) pour</p> <p>Haemophilia A</p> <p>Therapeutic equivalent to cryoprecipitate (pathogen-reduced) pour</p> <p>Von Willebrand disease</p>

Cryoprecipitate (pathogen-reduced)

Section	Indications
Blood and blood components Injection: frozen liquid in bag or lyophilized powder in vial containing: > 50 IU Factor VIII > 100 IU vWF > 140 mg clottable fibrinogen per unit	<p>Coagulation defects, purpura or other haemorrhagic or related conditions</p> <p>Obstetric haemorrhage</p> <p>Haemophilia A</p> <p>Von Willebrand disease</p>

Dextran 40

Section	Indications
Plasma substitutes	Hypovolaemia

Dextran 70

Section	Indications
Plasma substitutes Parenteral > General injections > IV: 6% injectable solution	Hypovolaemia

Fresh-frozen plasma

Section	Indications
Blood and blood components Parenteral > General injections > IV:	Blood transfusion without reported diagnosis

Normal immunoglobulin

Section

Human immunoglobulins

Parenteral > General injections > IV: 5% protein solution; 10% protein solution

Parenteral > General injections > IM: 16% protein solution

Parenteral > General injections > SC: 15% protein solution; 16% protein solution

Indications

Primary immunodeficiencies

Langerhans cell histiocytosis

Mucocutaneous lymph node syndrome

Platelets

Section

Blood and blood components

Parenteral > General injections > IV:

Indications

Blood transfusion without reported diagnosis

Polygeline

Section

Plasma substitutes

Parenteral > General injections > IV: 3.5% injectable solution

Parenteral > General injections > IV: 3.5% in solution

Indications

Therapeutic equivalent to [dextran 70](#) pour

Hypovolaemia

Hypovolaemia

Red blood cells

Section

Blood and blood components

Parenteral > General injections > IV:

Indications

Blood transfusion without reported diagnosis

Whole blood

Section

Blood and blood components

Parenteral > General injections > IV:

Indications

Blood transfusion without reported diagnosis